Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT02719613Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2016
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Jul 2016; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02719613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719613.